INV 321
Alternative Names: INV-321Latest Information Update: 28 Jun 2024
Price :
$50 *
At a glance
- Originator Invenra
- Class Antineoplastics; Bispecific antibodies; Drug conjugates; Immunoconjugates; Immunotherapies; Peptides
- Mechanism of Action Immunomodulators; Regulatory T-lymphocyte modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for research development in Cancer in USA (Parenteral)